Search Reports:
  Search
spacer
MORE INFORMATIONarrow
Not sure this is the report that you need? Have questions about the report before purchasing? We're here to help!
HOW TO ORDERarrow
Ordering reports couldn't be easier. Select the license for your needs, click Order Now, and complete our streamlined checkout process. We accept major credit cards, wire/bank transfers, and checks.

MC, Visa, AMEX, Diners, Discovery, JCB
MORE OPTIONSarrow
ABOUT THE PUBLISHERarrow
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.

Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022

Published by GlobalData on Dec 31, 2012 - 55 pages
PDF format - Delivered by Email within 1 business day
License Options Question


Report Abstract Table of Contents Request Sample
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Efficacy at Prolonging Overall Survival
6.3 Safety
6.4 Mitigation of Symptoms
6.5 Cost
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Custirsen Sodium
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment
9.4.2 Percent Drug-treated Patients
9.4.3 Percent Hormone Therapy-Treated Patients
9.4.4 General Pricing Assumptions
9.4.5 Individual Drug Assumptions
9.4.6 Generic Erosion
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets
Table 2: Global Variations in Recommendations on Routine PSA Screening
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012
Table 5: Leading Treatments for Prostate Cancer, 2012
Table 6: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment
Table 7: Overall Unmet Needs, CRPC - Current Level of Attainment
Table 8: Clinical Unmet Needs - Gap Analysis, 2012
Table 9: Prostate Cancer - Phase III Pipeline, 2012
Table 10: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012
Table 11: Product Profile - Custirsen Sodium
Table 12: Custirsen Sodium SWOT Analysis, 2012
Table 13: Global Sales Forecasts ($m) for Custirsen Sodium, 2012-2022
Table 14: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022






Copyright © 2014 Fast Market Research, Inc.